Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. / Holmager, Pernille; Langer, Seppo W; Federspiel, Birgitte; Willemoe, Gro Linno; Garbyal, Rajendra Singh; Melchior, Linea; Klose, Marianne; Kjaer, Andreas; Hansen, Carsten Palnaes; Andreassen, Mikkel; Knigge, Ulrich.
In: Journal of Neuroendocrinology, Vol. 33, No. 9, e13018, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms
AU - Holmager, Pernille
AU - Langer, Seppo W
AU - Federspiel, Birgitte
AU - Willemoe, Gro Linno
AU - Garbyal, Rajendra Singh
AU - Melchior, Linea
AU - Klose, Marianne
AU - Kjaer, Andreas
AU - Hansen, Carsten Palnaes
AU - Andreassen, Mikkel
AU - Knigge, Ulrich
N1 - © 2021 British Society for Neuroendocrinology.
PY - 2021
Y1 - 2021
N2 - An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.
AB - An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.
U2 - 10.1111/jne.13018
DO - 10.1111/jne.13018
M3 - Journal article
C2 - 34414612
VL - 33
JO - Journal of Neuroendocrinology
JF - Journal of Neuroendocrinology
SN - 0953-8194
IS - 9
M1 - e13018
ER -
ID: 276655690